Twitter

11/3/2009 - Teva Pharmaceutical Industries (NASDAQ:TEVA) reported Q3 EPS of $0.89, ex-items, beating consensus analyst estimates of $0.88. Revenue for the quarter rose 24.9% year-over-year to $3.55 billion, falling short of consensus estimates of $3.63 billion. President and CEO Shlomo Yanai said, "This was another very strong quarter for Teva, with record-breaking financial results across the board . . . In fact, for the first time, we crossed the billion dollar mark in quarterly cash flow from operations. All of our business units and geographies continued to grow during the quarter, with especially strong sales of Copaxone®, which continued to strengthen its position as the worldâ€(TM)s leading therapy for the treatment of multiple sclerosis, and of ProAirâ„¢, the leading Albuterol inhaler in the U.S.”

Contact Chip Brian

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at www.TradeTheTrend.com/signup.html